Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Brentuximab vedotin + Carboplatin + Etoposide + Ifosfamide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Brentuximab vedotin||Adcetris||SGN-35||Adcetris (brentuximab vedotin) is an antibody-drug conjugate comprised of a monoclonal antibody targeting CD30 linked to the tubulin-binding drug MMAE, which binds CD30-expressing cells and disrupts microtubule polymerization, potentially resulting in decreased tumor growth (PMID: 22684302). Adcetris (brentuximab vedotin) is FDA approved for Hodgkin lymphoma, anaplastic large cell lymphoma, CD30-expressing mycosis fungoides, and in combination with chemotherapy in other CD30-expressing peripheral T-cell lymphomas (FDA.gov).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Etoposide||Vepesid||EPEG|Eposin|VP-16|VP-16-213||TOPO2 inhibitor 4||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Ifosfamide||Cyfos||Z4942||Chemotherapy - Alkylating 14||Cyfos (ifosfamide) is an alkylating agent, which cross-links DNA, thereby inhibiting DNA replication (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02227199||Phase Ib/II||Brentuximab vedotin + Carboplatin + Etoposide + Ifosfamide||Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)||Active, not recruiting|